In a bold push to bolster domestic manufacturing, former U.S. President Donald Trump has announced a 100% tariff on imported branded and patented pharmaceutical drugs, set to take effect from October 1, 2025, unless the producing company is in the process of constructing a manufacturing facility on American soil.
The announcement, made via Trump’s social media platform Truth Social, signals a renewed push to promote domestic manufacturing and reduce reliance on foreign pharmaceutical supply chains. Trump specified that companies with U.S.-based plants that are either “breaking ground” or “under construction” will be exempt from the new levies.
This development carries significant implications for India’s pharmaceutical industry, which counts the U.S. as its single largest export destination. In FY24 alone, India exported $8.7 billion worth of pharmaceutical goods to the American market, representing nearly a third of its total overseas sales. That momentum continued into the first half of 2025, with another $3.7 billion in exports heading to the U.S., according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil).
Indian drugmakers such as Sun Pharma, Dr. Reddy’s Laboratories, Aurobindo Pharma, Zydus Lifesciences, and Gland Pharma, many of which derive between 30% and 50% of their revenue from the U.S., could face renewed pressure under the proposed tariff regime. While the initial target appears to be high-value, branded and patented drugs typically produced by multinational giants, the scope and definitions around “branded” remain ambiguous, leaving room for concern over the future of complex generics and specialty medicines.
Indian firms are critical to the U.S. healthcare ecosystem, supplying nearly half of its generic drugs and a significant share of biosimilars. These products are essential to keeping healthcare costs down, particularly in areas with limited access to expensive branded treatments. Industry analysts warn that additional tariffs could disrupt supply chains, increase drug prices for American consumers, and cause shortages, especially as many Indian manufacturers operate on tight profit margins and may be unable to absorb the cost burden.
As the 2024 election cycle continues to unfold, the announcement reinforces Trump’s commitment to using tariffs as a central economic and political tool, one that could have ripple effects well beyond the pharmaceutical sector.
